Athersys finishes enrolling heart attack patients for stem cell therapy study
CLEVELAND, Ohio – Biopharmaceutical company Athersys Inc. has finished enrolling patients for a phase 1 clinical trial of its MultiStem adult stem cell therapy to treat heart attack victims.
[Read the full article here]Related News:
Athersys finishes enrolling heart attack patients for stem cell …
Athersys still looking for funders of stem cell study for stroke patients
Athersys stem cell therapy could offer new heart attack treatment